Enrollment change • Combination therapy
|
PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • IRF4 (Interferon regulatory factor 4)
|
ALK positive • BCL6 rearrangement • BCL2 rearrangement
|
Keytruda (pembrolizumab) • maplirpacept (TTI-622) • ontorpacept (PF-07901800)